{"transactions":[{"id":732117,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:06:11.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":395895,"source":{"system":"sec-edgar","filing":"0001356256-26-000005","document":"wk-form4_1781813168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000135625626000005/wk-form4_1781813168.xml","form_type":"4"}},{"id":912690,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":10.18,"underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912689,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":11.85,"underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912688,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":11.2,"underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912687,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":11.68,"underlying":"Common Stock","underlying_shares":16875},"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912686,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":17.55,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912685,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock - Restricted Stock Units","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":912684,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T16:15:20.000Z","date":"2026-02-10","kind":"other","planned":false,"acquired":false,"shares":3800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001356256-26-000002","document":"form4-02102026_040209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000135625626000002/form4-02102026_040209.xml","form_type":"4"}},{"id":1057068,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-25T08:50:44.000Z","date":"2025-08-22","kind":"purchase","planned":false,"acquired":true,"shares":3800,"price":10.82,"value":41116.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased on open market. All shares purchased at one price."}],"balance_after":35004,"source":{"system":"sec-edgar","filing":"0001029142-25-000120","document":"wk-form4_1756126240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000120/wk-form4_1756126240.xml","form_type":"4"}},{"id":1106355,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:12:25.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":338795,"source":{"system":"sec-edgar","filing":"0001725160-25-000129","document":"wk-form4_1750277537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000129/wk-form4_1750277537.xml","form_type":"4"}},{"id":1112265,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T17:51:37.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":28500,"derivative":{"exercise_price":10.18,"expiration_date":"2032-06-10","underlying":"Commont Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001029142-25-000102","document":"wk-form4_1749851491.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000102/wk-form4_1749851491.xml","form_type":"4"}},{"id":1112264,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T17:51:37.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company."}],"balance_after":31204,"source":{"system":"sec-edgar","filing":"0001029142-25-000102","document":"wk-form4_1749851491.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000102/wk-form4_1749851491.xml","form_type":"4"}},{"id":1163389,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T21:07:20.000Z","date":"2025-04-30","kind":"purchase","planned":false,"acquired":true,"shares":21000,"price":1.3987,"value":29372.7,"ownership":{"direct":true},"balance_after":281192,"source":{"system":"sec-edgar","filing":"0001725160-25-000094","document":"wk-form4_1746047232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000094/wk-form4_1746047232.xml","form_type":"4"}},{"id":1366633,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T22:46:58.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":260192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":260192,"source":{"system":"sec-edgar","filing":"0001725160-24-000186","document":"wk-form4_1731538012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000186/wk-form4_1731538012.xml","form_type":"4"}},{"id":1500891,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:32:55.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":11.85,"expiration_date":"2031-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-065592","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017024065592/ownership.xml","form_type":"4"}},{"id":1500890,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-28T20:32:55.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":5357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company."}],"balance_after":25446,"source":{"system":"sec-edgar","filing":"0000950170-24-065592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017024065592/ownership.xml","form_type":"4"}},{"id":1583752,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:24:59.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.657,"underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0000950170-24-029443","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017024029443/ownership.xml","form_type":"4"}},{"id":1583751,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:24:59.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":20.1,"underlying":"Common Stock","underlying_shares":2033},"source":{"system":"sec-edgar","filing":"0000950170-24-029443","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017024029443/ownership.xml","form_type":"4"}},{"id":1583750,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T21:24:59.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 19,900 restricted stock units (\"RSUs\") which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017024029443/ownership.xml","form_type":"4"}},{"id":1691332,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T21:30:54.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":2048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $23,875"}],"balance_after":22666,"source":{"system":"sec-edgar","filing":"0000950170-24-000962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017024000962/ownership.xml","form_type":"4"}},{"id":1728436,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:26:56.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":20618,"source":{"system":"sec-edgar","filing":"0001209191-23-056797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919123056797/doc4.xml","form_type":"4"}},{"id":1740602,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T22:16:10.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87500,"price":0.93,"value":81375.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.13,"expiration_date":"2033-01-01","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001453687-23-000083","document":"wk-form4_1700086561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000083/wk-form4_1700086561.xml","form_type":"4"}},{"id":1740601,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T22:16:10.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger."}],"balance_after":0,"derivative":{"exercise_price":3.31,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001453687-23-000083","document":"wk-form4_1700086561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000083/wk-form4_1700086561.xml","form_type":"4"}},{"id":1740600,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T22:16:10.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.01,"expiration_date":"2031-03-29","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001453687-23-000083","document":"wk-form4_1700086561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000083/wk-form4_1700086561.xml","form_type":"4"}},{"id":1740599,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T22:16:10.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger."}],"balance_after":0,"derivative":{"exercise_price":3,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001453687-23-000083","document":"wk-form4_1700086561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000083/wk-form4_1700086561.xml","form_type":"4"}},{"id":1740598,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-15T22:16:10.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the \"Merger\") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the \"Merger\") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc."}],"balance_after":0,"derivative":{"exercise_price":2.1,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001453687-23-000083","document":"wk-form4_1700086561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000083/wk-form4_1700086561.xml","form_type":"4"}},{"id":1770200,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T21:36:54.000Z","date":"2023-10-01","kind":"grant","planned":false,"acquired":true,"shares":5797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $23,875."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares reflect 1:10 reverse stock split effective September 1, 2023."}],"balance_after":15618,"source":{"system":"sec-edgar","filing":"0001209191-23-051150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919123051150/doc4.xml","form_type":"4"}},{"id":1833575,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T22:34:50.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":35634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $23,875."}],"balance_after":98215,"source":{"system":"sec-edgar","filing":"0001209191-23-041668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919123041668/doc4.xml","form_type":"4"}},{"id":1844958,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-23T20:36:37.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":46000,"derivative":{"exercise_price":0.6657,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001209191-23-039415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919123039415/doc4.xml","form_type":"4"}},{"id":1873682,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-31T17:35:33.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":11.2,"expiration_date":"2030-05-25","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-23-033178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123033178/doc4.xml","form_type":"4"}},{"id":1873681,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T17:35:33.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":5357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. The reporting person has reported prior awards of restricted stock units in Table II on Form 4. The total reported in Column 5 includes 5,357 newly awarded restricted stock units and 14,732 restricted stock units previously reported in Table II."}],"balance_after":20089,"source":{"system":"sec-edgar","filing":"0001209191-23-033178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123033178/doc4.xml","form_type":"4"}},{"id":1920802,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-12T23:05:46.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":25.3697,"value":101478.8,"ownership":{"direct":true},"balance_after":259500,"source":{"system":"sec-edgar","filing":"0000950170-23-012595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017023012595/ownership.xml","form_type":"4"}},{"id":1927185,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T21:06:07.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":34925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $23,875."}],"balance_after":62581,"source":{"system":"sec-edgar","filing":"0001209191-23-022805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919123022805/doc4.xml","form_type":"4"}},{"id":1956491,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-13T20:06:51.000Z","date":"2023-03-13","kind":"purchase","acquired":true,"shares":5500,"price":29.1499,"value":160324.45,"ownership":{"direct":true},"balance_after":255500,"source":{"system":"sec-edgar","filing":"0000950170-23-007570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000095017023007570/ownership.xml","form_type":"4"}},{"id":2028145,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T23:55:55.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":35.8,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-23-004238","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000089924323004238/doc4.xml","form_type":"4"}},{"id":2028144,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-07T23:55:55.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units that vest 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0000899243-23-004238","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000089924323004238/doc4.xml","form_type":"4"}},{"id":2067126,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T22:06:11.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying this award will vest in full on January 2, 2024."}],"balance_after":87500,"derivative":{"exercise_price":1.13,"expiration_date":"2033-01-01","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001453687-23-000025","document":"wf-form4_167286995410639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000025/wf-form4_167286995410639.xml","form_type":"4"}},{"id":2221855,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-24T22:48:04.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":20334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":20334,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":20334},"source":{"system":"sec-edgar","filing":"0001209191-22-039327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919122039327/doc4.xml","form_type":"4"}},{"id":2254039,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T17:01:45.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":16875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":16875,"derivative":{"exercise_price":11.68,"expiration_date":"2029-05-25","underlying":"Common Stock","underlying_shares":16875},"source":{"system":"sec-edgar","filing":"0001209191-22-032617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122032617/doc4.xml","form_type":"4"}},{"id":2254038,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-27T17:01:45.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":4018,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."}],"balance_after":4018,"derivative":{"underlying":"Common Stock","underlying_shares":4018},"source":{"system":"sec-edgar","filing":"0001209191-22-032617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122032617/doc4.xml","form_type":"4"}},{"id":2443745,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T21:34:37.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Common Stock underlying this award will vest in full on January 3, 2023."}],"balance_after":40000,"derivative":{"exercise_price":3.31,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001453687-22-000021","document":"wf-form4_164141846145841.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000021/wf-form4_164141846145841.xml","form_type":"4"}},{"id":2502367,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T18:33:02.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":9.51,"expiration_date":"2031-05-03","underlying":"Common Shares","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001104659-21-141750","document":"tm2133436-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000110465921141750/tm2133436-2_4seq1.xml","form_type":"4"}},{"id":2534412,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-10-26T20:22:58.000Z","date":"2021-10-25","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, the stock option shall be fully vested and exercisable on the first anniversary of the vesting commencement date, October 25, 2022."}],"balance_after":10167,"derivative":{"exercise_price":6.31,"expiration_date":"2031-10-25","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-061631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919121061631/doc4.xml","form_type":"4"}},{"id":2537547,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-21T17:04:38.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant vests over three years with 1/3 vesting on each annual anniversary of October 19, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":17.55,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-21-061277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919121061277/doc4.xml","form_type":"4"}},{"id":2537546,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-10-21T17:04:38.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":10714,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of October 19, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date.  The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of October 19, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date.  The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of October 19, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date.  The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of October 19, 2021, provided that Reporting Person continues to provide services to the Company through each vesting date.  The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."}],"balance_after":10714,"derivative":{"underlying":"Common Stock","underlying_shares":10714},"source":{"system":"sec-edgar","filing":"0001209191-21-061277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919121061277/doc4.xml","form_type":"4"}},{"id":2712004,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-15T00:03:56.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022."}],"balance_after":10167,"derivative":{"exercise_price":23.2,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-032960","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919121032960/doc4a.xml","form_type":"4/A","original_submission_date":"2021-05-07"}},{"id":2722633,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-08T01:56:41.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":22.5,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-031107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919121031107/doc4.xml","form_type":"4"}},{"id":2726758,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-05T20:16:26.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly installments over the following two years."}],"balance_after":67000,"derivative":{"exercise_price":9.51,"expiration_date":"2031-05-03","underlying":"Common Shares","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001062993-21-004146","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000106299321004146/form4.xml","form_type":"4"}},{"id":2763854,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-01T22:31:41.000Z","date":"2021-03-30","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on March 30, 2022."}],"balance_after":40000,"derivative":{"exercise_price":4.01,"expiration_date":"2031-03-29","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001453687-21-000046","document":"wf-form4_161731624881899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000046/wf-form4_161731624881899.xml","form_type":"4"}},{"id":2978781,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:42:45.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001104659-20-126320","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126320/a4.xml","form_type":"4"}},{"id":3101865,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-23T20:47:06.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 19, 2021 or the day immediately prior to the company's 2021 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":3,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001453687-20-000077","document":"wf-form4_159294520886842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368720000077/wf-form4_159294520886842.xml","form_type":"4"}},{"id":3128810,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-02T01:50:42.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-20-033323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919120033323/doc4.xml","form_type":"4"}},{"id":3166932,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-30T17:02:40.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in four equal annual installments commencing on April 28, 2021."}],"balance_after":1000000,"derivative":{"exercise_price":8.2,"expiration_date":"2030-04-28","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000792977-20-000037","document":"wf-form4_158828054244692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000037/wf-form4_158828054244692.xml","form_type":"4"}},{"id":3331197,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2019-12-26T22:29:44.000Z","date":"2019-12-23","kind":"grant","acquired":true,"shares":19704,"price":0.125,"value":2463.0,"ownership":{"direct":true},"balance_after":19704,"derivative":{"exercise_price":1.46,"exercise_date":"2019-12-23","expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":19704},"source":{"system":"sec-edgar","filing":"0001104659-19-076220","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000110465919076220/a4.xml","form_type":"4"}},{"id":3331196,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-26T22:29:44.000Z","date":"2019-12-23","kind":"grant","acquired":true,"shares":39409,"price":1.46,"value":57537.14,"ownership":{"direct":true},"balance_after":80845,"source":{"system":"sec-edgar","filing":"0001104659-19-076220","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000110465919076220/a4.xml","form_type":"4"}},{"id":3433133,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-20T20:32:32.000Z","date":"2019-08-20","kind":"grant","acquired":true,"shares":41436,"price":1.81,"value":74999.16,"ownership":{"direct":true},"balance_after":41436,"source":{"system":"sec-edgar","filing":"0001453687-19-000124","document":"wf-form4_156633313666723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368719000124/wf-form4_156633313666723.xml","form_type":"4"}},{"id":3486118,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-18T20:21:24.000Z","date":"2019-06-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":2.1,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001453687-19-000071","document":"wf-form4_156088926892404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368719000071/wf-form4_156088926892404.xml","form_type":"4"}},{"id":3500122,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-05T21:30:10.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":11.84,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-19-034848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356256/000120919119034848/doc4.xml","form_type":"4"}},{"id":3998151,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998150,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":6300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F13","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The restricted stock units were granted on November 10, 2017 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998149,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998148,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998147,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $360,600.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":3.99,"expiration_date":"2027-09-18","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998146,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,018,400.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":4.64,"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998145,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":474810,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,386,445.20, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of April 4, 2016, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":7.08,"expiration_date":"2026-04-04","underlying":"Common Stock","underlying_shares":474810},"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":3998144,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-13T18:07:08.000Z","date":"2018-03-09","kind":"other","acquired":false,"shares":56787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the \"Merger Agreement\"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share (\"Offer Price\"), net to the seller in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-007300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007300/doc4.xml","form_type":"4"}},{"id":4079036,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2018-02-02T17:54:57.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Approximately 70% of each RSU represents a contingent right to receive approximately 0.70 share of the issuer's Common Stock upon vesting and approximately 30% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of the shares underlying the RSU vest on each of February 1, 2019, February 1, 2020, February 1, 2021 and February 1, 2022, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":250000,"derivative":{"expiration_date":"2022-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-007135","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919118007135/doc4.xml","form_type":"4"}},{"id":4099288,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2018-01-16T17:26:33.000Z","date":"2018-01-11","kind":"exercise","acquired":false,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":31500,"derivative":{"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-18-003646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919118003646/doc4.xml","form_type":"4"}},{"id":4099287,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-01-16T17:26:33.000Z","date":"2018-01-11","kind":"tax_withholding","acquired":false,"shares":3429,"price":3.92,"value":13441.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"3,429 shares of the restricted share unit (\"RSU\") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"3,429 shares of the restricted share unit (\"RSU\") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."}],"balance_after":56787,"source":{"system":"sec-edgar","filing":"0001209191-18-003646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919118003646/doc4.xml","form_type":"4"}},{"id":4099286,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-01-16T17:26:33.000Z","date":"2018-01-11","kind":"exercise","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60216,"source":{"system":"sec-edgar","filing":"0001209191-18-003646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919118003646/doc4.xml","form_type":"4"}},{"id":4165373,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-11-13T20:00:49.000Z","date":"2017-11-10","kind":"grant","acquired":true,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":6300,"derivative":{"expiration_date":"2021-09-18","underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001209191-17-060478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117060478/doc4.xml","form_type":"4"}},{"id":4204715,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-09-20T21:07:09.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":15500,"derivative":{"expiration_date":"2021-09-18","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-17-053535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117053535/doc4.xml","form_type":"4"}},{"id":4204714,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-09-20T21:07:09.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable at the rate of 1/4th of the total shares on September 18, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":3.99,"expiration_date":"2027-09-18","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-053535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117053535/doc4.xml","form_type":"4"}},{"id":4235217,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-08-14T17:12:54.000Z","date":"2017-08-11","kind":"purchase","acquired":true,"shares":5500,"price":3.735,"value":20542.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price.  These shares were bought in multiple transactions at prices ranging from $3.728 to $3.76 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote."}],"balance_after":49716,"source":{"system":"sec-edgar","filing":"0001209191-17-048790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117048790/doc4.xml","form_type":"4"}},{"id":4318135,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-05-16T17:43:19.000Z","date":"2017-05-12","kind":"purchase","acquired":true,"shares":2800,"price":3.997,"value":11191.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price.  These shares were bought in multiple transactions at prices ranging from $3.9969 to $3.9975 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44216,"source":{"system":"sec-edgar","filing":"0001209191-17-032832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117032832/doc4.xml","form_type":"4"}},{"id":4360782,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-04-04T17:39:42.000Z","date":"2017-03-31","kind":"purchase","acquired":true,"shares":2000,"price":4.1143,"value":8228.6,"ownership":{"direct":true},"balance_after":41416,"source":{"system":"sec-edgar","filing":"0001209191-17-025174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117025174/doc4.xml","form_type":"4"}},{"id":4376431,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-21T20:09:52.000Z","date":"2017-03-20","kind":"purchase","acquired":true,"shares":1000,"price":3.9271,"value":3927.1,"ownership":{"direct":true},"balance_after":39416,"source":{"system":"sec-edgar","filing":"0001209191-17-022141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117022141/doc4.xml","form_type":"4"}},{"id":4475206,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T16:55:47.000Z","date":"2017-01-27","kind":"purchase","acquired":true,"shares":20500,"price":3.758,"value":77039.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price.  These shares were bought in multiple transactions at prices ranging from $3.695 to $3.8435 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock.  The number of shares above reflects the reverse stock split."}],"balance_after":38416,"source":{"system":"sec-edgar","filing":"0001209191-17-006410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117006410/doc4.xml","form_type":"4"}},{"id":4491020,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-01-13T19:48:19.000Z","date":"2017-01-11","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":42000,"derivative":{"expiration_date":"2021-01-11","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-17-003757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117003757/doc4.xml","form_type":"4"}},{"id":4491019,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-13T19:48:19.000Z","date":"2017-01-11","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":190000,"derivative":{"exercise_price":4.64,"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001209191-17-003757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117003757/doc4.xml","form_type":"4"}}]}